Guselkumab has received approval for moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.1 ...

Japan's Takeda Pharmaceutical said on Thursday its experimental pill for a type of skin disease, developed using artificial ...

AbbVie (NYSE: ABBV) has the highest share price of any stock on this list, at more than $200 each. But don't let the price scare you away -- this is a solid dividend stock that's raised its payout ...

On December 10, HSBC increased its price target on AbbVie Inc. (NYSE:ABBV) from $225 to $265 and also upgraded the stock to Buy.

The Pharmaceutical Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar. This drugmaker has a strong ...

Investing.com - AbbVie has lifted its annual profit guidance, after solid demand for the pharmaceutical group’s Skyrizi psoriasis drug helped third-quarter sales surpass estimates. The Illinois-based ...

Skyrizi (risankizumab-rzaa) is a biologic medication doctors prescribe to treat certain autoimmune and inflammatory conditions. Like any medication, it can cause side effects. But is one of Skyrizi’s ...

Psoriasis is a chronic autoimmune skin condition causing red, scaly patches. It can appear on various body parts, including the scalp, elbows, knees, hands, feet, lower back, torso, face, and ...

Medicare may cover Skyrizi (risankizumab-rzaa) if you have a plan with prescription drug benefits, such as a Part D or Medicare Advantage (Part C) plan. Skyrizi is a brand-name, biologic drug that ...

A Johnson & Johnson banner is displayed on the front of the NYSE in New York (Reuters) -Johnson & Johnson said on Friday its experimental psoriasis drug met the main goal of a late-stage study, as the ...

(Reuters) -Johnson & Johnson said on Friday its experimental psoriasis drug met the main goal of a late-stage study, as the once-daily pill helped patients achieve clear or almost clear skin. The ...

Some 25% of patients with psoriasis eventually develop psoriatic arthritis, but the risk may be mitigated with targeted therapies. This single-center study found that progression to PsA was more ...